[Heavyweight] 3 billion domestic insulin dragon hair varieties will be approved

A few days ago, the marketing application of 15 kinds of therapeutic biological products protamine recombinant human insulin injection (premixed 30R) of Ganli Pharmaceutical has entered the administrative approval stage.

Source: official website of the State Drug Administration

Protamine recombinant human insulin is human insulin produced by recombinant DNA technology.

At present, the main preparation products of protamine recombinant human insulin that have been marketed in China are protamine recombinant human insulin injection, protamine recombinant human insulin injection (premixed 30R), and protamine recombinant human insulin injection (premixed 30/70) Among them, the sales of protamine recombinant human insulin injection (premixed 30R) accounted for the largest proportion, and this product was only sold by the original manufacturer.

According to data from Minai.

Ganli Pharmaceutical submitted a listing application for protamine recombinant human insulin injection (premixed 30R) in 2015, and entered the administrative approval stage in the near future, and is expected to win the first domestic product.

2020 China's public medical institutions' terminal insulin and similar drugs TOP5 companies

Source: Mi Nei.

The concentration of domestic insulin and its analogue manufacturers is relatively high, and the total market share of TOP5 companies exceeds 90%.

Diabetes medications that Ganli Pharmaceutical has reported for production

Source: Meinenet MED2.

At present, Ganli Pharmaceutical has applied for the market of 9 anti-diabetic drugs, 8 of which are insulin, including insulin aspart injection, insulin aspart 30 injection, protamine zinc recombinant insulin lispro mixed injection (25R), recombinant insulin lispro injection Liquid and recombinant insulin glargine injection have been approved for marketing.

Source: Minei.